Diagramming the development of MDS/AML after treatment with PARP inhibitors

The use of Poly (ADP-ribose) polymerase inhibitors (PARPi) for the treatment of ovarian cancer has steadily increased over the last decade. The risk of developing myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) after therapy with PARPi has been approximated at 1–3% though some recent studies have noted a higher incidence (4–8%). Here, we characterized a cohort of patients with post-PARPi MDS/AML, including associated clinical factors and outcomes in patients with ovarian cancer.